Background: Non-nasopharyngeal head and neck lymphoepithelioma-like carcinoma (LELC) is a rate entity. The purpose of this study was to analyze its demographic, clinicopathologic, and survival characteristics.
Methods: A cohort from the Surveillance, Epidemiology, and End Results (SEER) database of cases with non-nasopharyngeal head and neck LELC between 1973 and 2011.
Results: There were 378 cases with 5-year overall survival (OS) of 70.5% and disease-specific survival (DSS) of 77.7%. The majority of cases were <60-year-old white men. Salivary gland LELC had the highest OS (80.8%) and DSS (85.7%) at 5 years. Multivariate analysis showed that older age, no surgery, and no radiation were independently significantly associated with worse survival (p < .05).
Conclusion: Non-nasopharyngeal head and neck LELC is uncommon in the United States with salivary gland LELC having the highest OS and DSS compared with other head and neck sites. The optimal treatment with surgery and/or radiotherapy needs to be further investigated. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1294-E1300, 2016.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.24215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pediatric non-nasopharyngeal head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results (SEER) program with review of the literature.
Int J Pediatr Otorhinolaryngol
November 2024
Louisiana State University Health Sciences Center, Department of Otolaryngology-Head and Neck Surgery, New Orleans, LA, USA; Children's Hospital of New Orleans, Division of Otolaryngology, New Orleans, LA, USA. Electronic address:
Article Synopsis
- Head and neck squamous cell carcinoma (HNSCC) is rare in pediatric patients compared to adults, where other tumors like lymphomas are more common; the disease's association with the human papillomavirus raises concerns about its prevalence and impact on children's health.
- This study examined data from the National Cancer Institute’s SEER database to analyze the incidence, characteristics, treatments, and survival rates of pediatric HNSCC cases from 1973 to 2019, identifying 292 cases primarily affecting males and older children.
- Results showed that nasopharynx is the most common site for HNSCC in children, with a notable overall 5-year survival rate of 83.6%, and the disease tends to be more
Effect of bilateral superficial parotid gland sparing IMRT on xerostomia and QOL: A prospective study.
J Cancer Res Ther
July 2024
Department of Radiation Oncology, Ramaiah Medical College, Bengaluru, Karnataka, India.
Background: Superficial lobe constitutes 80% of the parotid and is situated lateral to mandible and can be better spared during intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC). This study aimed to see the impact of bilateral superficial parotid gland (PG) sparing IMRT on xerostomia and quality of life (QOL) in patients with HNC receiving radiation.
Study Design: Prospective, questionnaire-based study.
Enhancing the management of locally advanced head and neck malignancies and cases with local/neck recurrence and metastasis through the integration of anlotinib with concurrent radiochemotherapy.
Anticancer Drugs
September 2024
Departments of Oncology.
The aim of this study is to assess the effectiveness and safety of anlotinib in conjunction with concurrent radiochemotherapy for the treatment of locally advanced head and neck malignant tumors, including cases exhibiting local or neck recurrence and metastasis. Between June 2020 and June 2023, 42 patients diagnosed with locally advanced head and neck malignant tumors or presenting with local or neck recurrence and metastasis were recruited. These individuals received treatment that combined anlotinib with concurrent radiochemotherapy, followed by a minimum of two cycles of oral anlotinib upon completion of the initial treatment regimen.
View Article and Find Full Text PDFReal-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Eur Arch Otorhinolaryngol
September 2024
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Objectives: Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval for recurrent or metastatic HNC based on the Phase III CheckMate 141 trial.
View Article and Find Full Text PDFVolumetric brain assessment of long-term head and neck cancer survivors.
Radiother Oncol
February 2024
University of Alabama at Birmingham, Department of Radiation Oncology, United States; University of Alabama at Birmingham, Institute for Cancer Outcomes and Survivorship, United States. Electronic address:
Background: Radiation therapy (RT) for locally advanced head and neck cancer (HNC) often exposes subcortical brain structures to radiation. We performed this study to assess region-specific brain volumetrics in a population of long term HNC survivors.
Methods And Materials: Forty HNC survivors were enrolled at a mean of 6.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!